Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606914 · ClinicalTrials.gov registry record · Phase 2
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Cancer and Primary Peritoneal Cancer, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 9
- Study locations
NCT04606914 is a Phase 2 study of Ovarian Cancer and Primary Peritoneal Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT04606914, a Phase 2 study of Ovarian Cancer and Primary Peritoneal Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 9
- Study locations
Study Summary
The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients will receive NACT with one cycle of carboplatin, followed by mirvetuximab + carboplatin (if FRα +) every 21 days for three cycles prior to interval cytoreductive surgery (iCRS). A total of 70 will be included in the study. Following completion of 4 cycles total of NACT and after allowing for appropriate recovery of cycle # 4, patients eligible for surgery, will undergo an iCRS. Patients will then complete 3 more cycles of mirvetuximab + carboplatin for a total of 7 intended cycles of treatment. It is up to the treating physician if they want to add bevacizumab to the last 2 cycles or use any type of maintenance therapy. The decision to add bevacizumab or use maintenance therapy does not need to be made upfront. Patients will sign a screening consent form prior to tissue biopsy. If a patient is found to be FRα negative, their treating physician can select the treatment they deem appropriate and the patient will be declared a screen failure. Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP inhibitors.
Conditions Studied
Interventions
- DRUG mirvetuximab soravtansine (MIRV; IMGN853)
Study Locations (9)
Minnesota
- University of Minnesota - Masonic Cancer Center - Minneapolis
- Mayo Clinic - Rochester
Alabama
- University of Alabama at Birmingham Womens & Infants Center - Birmingham
California
- University of California San Francisco - San Francisco
Mississippi
- University of Mississippi Medical Center - Oxford
Ohio
- Ohio State University - Columbus
Oklahoma
- University of Oklahoma - Oklahoma City
Pennsylvania
- Allegheny Health Network - Pittsburgh
Virginia
- University of Virginia - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606914
The ClinicalTrials.gov registry entry for NCT04606914 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which mirvetuximab soravtansine (MIRV; IMGN853) is the first listed.
NCT04606914 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Minnesota, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04606914 about?
NCT04606914 is a clinical study titled "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer". The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rece...
What is the current status of trial NCT04606914?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-05-27. Estimated completion is 2028-05-31.
What conditions does trial NCT04606914 study?
This clinical trial studies the following conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube.
What interventions are being tested in trial NCT04606914?
The interventions under investigation include: mirvetuximab soravtansine (MIRV; IMGN853) (DRUG).
Who is sponsoring clinical trial NCT04606914?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606914 being conducted?
This trial has 9 study locations across Alabama, California, Minnesota, Mississippi, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.